Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912388 | 0.83 | MEN1 (0.43) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL19102486 | 0.83 | MEN1 (0.43) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL28670802 | 0.82 | MEN1 (0.60) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL12253598 | 0.82 | BTN3A1 (0.43) | MEN1KMT2ANPSR1SRCANPEP | |
| SCHEMBL19916085 | 0.80 | BTN3A1 (0.53) | MEN1KMT2ANPSR1SRCL3MBTL1 | |
| SCHEMBL13674150 | 0.80 | BTN3A1 (0.53) | MEN1KMT2ANPSR1SRCL3MBTL1 | |
| SCHEMBL10120981 | 0.80 | BTN3A1 (0.53) | MEN1KMT2ANPSR1SRCL3MBTL1 | |
| SCHEMBL14600547 | 0.79 | ANPEP (0.46) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL23542051 | 0.78 | ANPEP (0.40) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL19765979 | 0.78 | BTN3A1 (0.55) | MEN1KMT2ANPSR1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | MEN1 909/4885KMT2A 2126/4885NPSR1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.